Clinical Commissioning Policy Proposition: Bendamustine for relapsed multiple myeloma (all ages)

NHS England has carefully reviewed the evidence to treat relapsed multiple myeloma with bendamustine and has concluded that there is not sufficient evidence to consider making the treatment routinely available at this time.

Source:

NHS England